Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

DSMB Recommends Continuation of Phase 3 Study of Bria-IMT in Metastatic Breast Cancer

October 22nd 2025

A data safety monitoring board recommended the continuation of a study of Bria-IMT plus immune checkpoint inhibition in metastatic breast cancer.

Arlo-Cel Delivers High, Durable Responses With Manageable Safety in R/R Myeloma

October 22nd 2025

Arlo-cel achieved a high ORR and CR rate with durable responses and favorable safety in relapsed/refractory multiple myeloma.

Dr Lynam on the Efficacy of Trastuzumab Detruxtecan in HER2-Expressing Ovarian Cancer

October 22nd 2025

Sarah Lynam, MD, details key efficacy data from the phase 2 DESTINY-PanTumor02 trial, evaluating trastuzumab deruxtecan in HER2-expressing solid tumors.

FDA Accepts NDA for Nilotinib Biosimilar XS003 for Chronic Myeloid Leukemia

October 21st 2025

XS003 shows bioequivalence to nilotinib at half the dose with a reduced food effect for patients with CML.

Dr Lee on the Optimal Patient Population to Receive Proton Therapy for Advanced NSCLC

October 21st 2025

Percy Lee, MD, discusses different radiation modalities for patients with NSCLC, the increasing complexity of reirradiation, and the strategic use of SABR.

BTK Inhibitors, CAR T-Cell Therapies, and JAK Inhibitors Refine Hematologic Oncology Standards

October 21st 2025

Aaron Gerds, MD, MS, discusses the role of BTK inhibitors in CLL, real-world data with CAR T-cell therapies in LBCL, and JAK inhibitors for myelofibrosis.

ctDNA-Guided Adjuvant Atezolizumab Boosts DFS, OS in Muscle-Invasive Bladder Cancer

October 20th 2025

Adjuvant atezolizumab improved DFS and OS in patients with muscle-invasive bladder cancer who tested positive for ctDNA after radical cystectomy.

Adjuvant Alectinib Impresses in Updated ALINA Results for ALK+ NSCLC

October 20th 2025

Long-term data from the ALINA trail continued to support the use of adjuvant alectinib in resected, ALK-positive, early stage non–small cell lung cancer.

Dr Le on Early Efficacy Data With Sevabertinib Monotherapy in HER2-Mutant NSCLC

October 20th 2025

Xiuning Le, MD, PhD, discusses findings from the phase 1/2 SOHO-01 trial evaluating sevabertinib monotherapy in HER2-mutant advanced NSCLC.

Dr Jänne on OS Benefit With Osimertinib Plus Chemo by Poor Prognostic Factors in EGFR+ NSCLC

October 20th 2025

Pasi A. Jänne, MD, PhD, discusses OS outcomes with osimertinib with or without chemotherapy based on baseline prognostic factors in EGFR-mutant NSCLC.

FDA Awards Breakthrough Therapy Designation to Bezuclastinib for Non-Advanced Systemic Mastocytosis

October 20th 2025

Bezuclastinib received breakthrough therapy designation for pretreated non-advanced systemic mastocytosis, as well as for smoldering systemic mastocytosis.

FDA Accepts BLA Resubmission for RP1 Plus Nivolumab in Advanced Melanoma

October 20th 2025

Will the FDA approve a resubmitted biologics license application for RP1 plus nivolumab in advanced melanoma after progression on anti–PD-1 therapy?

Future Avenues of Research in Advanced NSCLC

October 20th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss future areas of research and unmet needs in non–small cell lung cancer.

Eye-Catching Data From the 2025 World Conference on Lung Cancer

October 20th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss key data from the 2025 World Conference on Lung Cancer.

Dr Jain on Considerations for Sequencing JAK Inhibitors in Myelofibrosis

October 20th 2025

Akriti G. Jain, MD, discusses factors that affect treatment sequencing with JAK inhibitors for the treatment of patients with myelofibrosis.

TROPION-Breast02 Data Support Dato-DXd as New First-Line SOC in Triple-Negative Breast Cancer

October 20th 2025

Dato-DXd improved PFS, OS, and response rates compared with chemotherapy in first-line TNBC, with manageable safety, per phase 3 TROPION-Breast02 data.

Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI/ADT Yields Superior PFS in PSMA+ mHSPC

October 19th 2025

Lutetium Lu 177 vipivotide tetraxetan plus an ARPI and ADT improved rPFS in metastatic hormone-sensitive prostate cancer.

Enfortumab Vedotin Plus Pembrolizumab Shows First-Line Activity in PD-L1+ Recurrent/Metastatic HNSCC

October 19th 2025

Enfortumab vedotin plus pembrolizumab demonstrated meaningful first-line clinical activity in PD-L1–positive recurrent or metastatic HNSCC.

Dr Hurvitz on Sustained Benefit With Adjuvant Ribociclib Plus AI Therapy in HR+/HER2– Breast Cancer

October 19th 2025

Sara A. Hurvitz, MD, FACP, shares 5-year efficacy updates from the phase 3 NATALEE trial in HR-positive HER2-negative breast cancer.

Dr Mayer on Efficacy Data With Giredestrant Plus Everolimus in ER+/HER2– Breast Cancer

October 19th 2025

Erica L. Mayer, MD, MPH, discusses primary efficacy outcomes for giredestrant in the phase 3 evERA trial in ER-positive, HER2-negative advanced breast cancer.